Clinical Trial

Evaluation of Mirabegron Versus Tamsulosin or Their Combination in Treatment of Lower Urinary Tract Symptoms

Completed
View on ClinicalTrials.gov →
Summary
Stent related symptoms (SRSs) comprise of complaints such as irritative symptoms, sense of incomplete emptying, flank and suprapubic pain, and incontinence. Mechanical irritation of trigone, urinary reflux, and stent movement are plausible causes for SRSs. Alpha-blockers are the primary medications for ureteral stent-related symptoms. These medications are suggested to patients by the American Urological Association (AUA)/Endourological Society guideline to reduce stent-related symptoms with moderate recommendation. Nevertheless, there are many side effects associated with alpha-blockers such as dizziness, headache, and orthostatic hypotension
Trial Details
NCT Number NCT07307261
Lead Sponsor Avraiem Talaat
Conditions Ureteric Stent-related Morbidity
Enrollment 300 participants
Start Date 2024-10-10
Primary Completion 2025-10-05 (estimated)
Study Completion 2025-10-10 (estimated)
Updated on ClinicalTrials.gov 2025-12-29